Colin Chong

Colin Chong

Auto-generated profile, based on publicly available information

Colin Chong

Exelixis, Inc., Alameda, California

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JHJeff Hsu
Jeff Hsu
CCColin Chong
Colin Chong
JSJeffrey Serrill
Jeffrey Serrill
LGLevina Goon
Levina Goon
JBJoan Balayan
Joan Balayan
PYPeiwen Yu
Peiwen Yu
The multi-receptor tyrosine kinase inhibitor XL092 has been developed to inhibit the activity of oncogenic targets, including MET, VEGFR2, and the TAM family of kinases TYRO3, AXL and MER. Presented here is a preclinical evaluation of XL092. XL092 causes a significant decrease in tumor MET and AXL phosphorylation (P < 0.01) in murine Hs 746T xenograft models relative to vehicle, and a 96% inhibition of VEGFR2 phosphorylation in murine lungs. Dose-dependent tumor growth inhibition with XL092 was observed in various murine xenograft models, with dose-dependent tumor regression seen in the NCI-H441 model. Tumor growth inhibition was enhanced with the combination of XL092 with anti-PD-1, anti-programmed death ligand-1 (PD-L1), or anti-CTLA-4 compared with any of these agents alone in the MC38 murine syngeneic model and with anti-PD-1 in the CT26 colorectal cancer survival model. In vivo, XL092 promoted a decrease in the tumor microvasculature and significant increases of peripheral CD4+ T cells and B cells and decreases in myeloid cells versus vehicle. Significant increases in CD8+ T cells were also observed with XL092 plus anti-PD-1 or anti-PD-L1 versus vehicle. In addition, XL092 promoted M2 to M1 repolarization of macrophages in vitro and inhibited primary human macrophage efferocytosis in a dose-dependent manner. In summary, XL092 was shown to have significant antitumor and immunomodulatory activity in animal models both alone and in combination with immune checkpoint inhibitors, supporting its evaluation in clinical trials.


3 April 2023
Verified
Other
Open access
JHJeff Hsu
Jeff Hsu
CCColin Chong
Colin Chong
JSJeffrey Serrill
Jeffrey Serrill
LGLevina Goon
Levina Goon
JBJoan Balayan
Joan Balayan
PYPeiwen Yu
Peiwen Yu
Supplementary Figures and Tables with adjoining Legends


3 April 2023
Verified
Other
Open access
JHJeff Hsu
Jeff Hsu
CCColin Chong
Colin Chong
JSJeffrey Serrill
Jeffrey Serrill
LGLevina Goon
Levina Goon
JBJoan Balayan
Joan Balayan
PYPeiwen Yu
Peiwen Yu
The multi-receptor tyrosine kinase inhibitor XL092 has been developed to inhibit the activity of oncogenic targets, including MET, VEGFR2, and the TAM family of kinases TYRO3, AXL and MER. Presented here is a preclinical evaluation of XL092. XL092 causes a significant decrease in tumor MET and AXL phosphorylation (P < 0.01) in murine Hs 746T xenograft models relative to vehicle, and a 96% inhibition of VEGFR2 phosphorylation in murine lungs. Dose-dependent tumor growth inhibition with XL092 was observed in various murine xenograft models, with dose-dependent tumor regression seen in the NCI-H441 model. Tumor growth inhibition was enhanced with the combination of XL092 with anti-PD-1, anti-programmed death ligand-1 (PD-L1), or anti-CTLA-4 compared with any of these agents alone in the MC38 murine syngeneic model and with anti-PD-1 in the CT26 colorectal cancer survival model. In vivo, XL092 promoted a decrease in the tumor microvasculature and significant increases of peripheral CD4+ T cells and B cells and decreases in myeloid cells versus vehicle. Significant increases in CD8+ T cells were also observed with XL092 plus anti-PD-1 or anti-PD-L1 versus vehicle. In addition, XL092 promoted M2 to M1 repolarization of macrophages in vitro and inhibited primary human macrophage efferocytosis in a dose-dependent manner. In summary, XL092 was shown to have significant antitumor and immunomodulatory activity in animal models both alone and in combination with immune checkpoint inhibitors, supporting its evaluation in clinical trials.

27 November 2025
Verified
Other
Open access
JHJeff Hsu
Jeff Hsu
CCColin Chong
Colin Chong
JSJeffrey Serrill
Jeffrey Serrill
LGLevina Goon
Levina Goon
JBJoan Balayan
Joan Balayan
PYPeiwen Yu
Peiwen Yu
Suppl Figure 4 from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER